drugset
drugset / Trial / NCT05253807

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

NCT05253807 ↗

Phase 2 Completed 8 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options

Timeline

Start
2022-04-29
Primary completion
2023-08-16
Completion
2023-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemigatinib Small molecule 13.5 mg —

Indications

non-small cell lung carcinoma